Susquehanna International Group, LLP Adc Therapeutics Sa Transaction History
Susquehanna International Group, LLP
- $688 Billion
- Q2 2025
A detailed history of Susquehanna International Group, LLP transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Susquehanna International Group, LLP holds 115,232 shares of ADCT stock, worth $475,908. This represents 0.0% of its overall portfolio holdings.
Number of Shares
115,232
Previous 103,780
11.03%
Holding current value
$475,908
Previous $146,000
110.96%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ADCT
# of Institutions
90Shares Held
67.5MCall Options Held
68.2KPut Options Held
75.8K-
Redmile Group, LLC San Francisco, CA15.7MShares$64.7 Million5.11% of portfolio
-
Prosight Management, LP Dallas, TX10.5MShares$43.2 Million7.6% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct7.76MShares$32.1 Million0.05% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.91MShares$24.4 Million0.57% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$14.7 Million0.0% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $321M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...